|
| Study reference | Intervention | Results |
|
| OPTIMOX1 [33] | Continuous FOLFOX-4 versus intermittent FOLFOX-7 | No significant reduction in grade 3 neuropathy in the intermittent arm |
|
CONcePT [34] | Continuous oxaliplatin versus intermittent oxaliplatin | Reduced grade 3 neuropathy in the intermittent arm |
| Ca/Mg versus placebo | No reduction in grade 3/4 neuropathy in Ca/Mg group |
| Gamelin et al. 2004 [40] | Ca and Mg versus historic control | Reduced grade 3 neuropathy in Ca/Mg group |
| CAIRO2 trial [41] | Ca/Mg versus no prevention treatment | No reduction in grade 3/4 neuropathy in Ca/Mg group |
| N04C7 trial [18] | Ca/Mg versus placebo | Reduced grade 2 or worse neuropathy in Ca/Mg group |
| Neuroxa trial (ongoing) [42] | Ca/Mg versus no prevention treatment | Reduced grade 3 neuropathy in Ca/Mg group |
| Cascinu et al. 2002 [43] | Glutathione versus placebo | Reduced grade 3 neuropathy with glutathione |
| Lin et al. 2006 [44] | N-acetylcysteine versus placebo | Reduced grades 2–4 neuropathy with N-acetylcysteine |
| Wang et al. 2007 [45] | Glutamine versus no treatment | Reduced grade 3 neuropathy with glutamine |
| Lu et al. 2008 [46] | Amifostine versus glutamine | Reduced grades 1-2 and 3-4 in amifostine group |
| Guo et al. 2011 [47] | Oral lipoic acid versus placebo | No statistical difference in treatment groups |
| Von Delius et al. 2007 [48] | Carbamazepine versus no prevention treatment | No statistical difference in treatment groups |
| Argyriou et al. 2006 [49] | Oxcarbazepine versus no prevention treatment | Reduction in incidence of neuropathy in oxcarbazepine group |
| Mitchell et al. 2006 [50] | Gabapentin versus no prevention treatment | No reduction in neuropathy |
| Durand et al. 2003 [51] | Venlafaxine versus placebo | Reduced grade 3 neuropathy |
| Cassidy et al. 2008 [16] | Xaliproden versus placebo | Reduced grade 3 during treatment, but no difference after finishing treatment |
|
